$ZVRA News

HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target

Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics

Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

Zevra Therapeutics Says Expects To Continue Engagement With The U.S. FDA In The H2 2026 To Explore Pathways To Accelerate Clinical Development

UPDATE: Zevra Therapeutics Q2 Adj. EPS $0.25 Beats $0.14 Estimate, Sales $39.663M Beat $33.572M Estimate

Zevra Therapeutics Q2 EPS $0.14 Beats $0.11 Estimate, Sales $39.663M Beat $33.881M Estimate

Zevra Therapeutics Announces Publication Of "Long-Term Real-World Safety And Effectiveness Of Arimoclomol In Individuals With NPC: Outcomes From US Early Access Program Over A 4-Year Period" In Molecular Genetics And Metabolism

Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $20

Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24

BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24

Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C

Zevra Therapeutics Receives Negative Opinion From EMA CHMP On Its Marketing Authorization Application For Arimoclomol For The Treatment Of Niemann-Pick Disease Type C

HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target

Zevra Therapeutics Announces Publication Of Arimoclomol In Infants With Niemann-Pick Disease Type C: Results From The Phase 2/3 Open-Label Pediatric Substudy In Molecular Genetics And Metabolism Reports

Maxim Group Maintains Buy on Zevra Therapeutics, Raises Price Target to $35

Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $29

BTIG Reiterates Buy on Zevra Therapeutics, Raises Price Target to $27

Canaccord Genuity Maintains Buy on Zevra Therapeutics, Raises Price Target to $29